Pricing Log in Create free account
Saturday 17 October 2026 Export LLY’s income statement to Excel — free account

Eli Lilly and Company

LLY Healthcare Drug Manufacturers General

Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024. In the quarter to June 2026, revenue grew 47.7%, EPS grew 26.2%, free cash flow grew 458.1% and total debt rose 37.6%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years, revenue growth for five.

1,257.03 5.42 +0.43%
Market cap
$1.18T
P/E
42.2×
Fwd P/E
33.1×
Dividend yield
0.53%
F-score
7/9
Altman Z
8.61
Beneish M
−1.91
Dividend safety
86/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Eli Lilly and Company (LLY) Revenue growth

Alert me on Revenue growth

Eli Lilly and Company's revenue growth over the twelve months to 30 June 2026 was 49.6%, up 4.9 percentage points from fiscal 2025 (44.7%). Over the past ten years it has ranged from −5.88% (fiscal 2017) to 44.7% (fiscal 2025) — the current reading is the highest in ten years. That is above the Drug Manufacturers General industry median of 6.66% and above the Healthcare sector median of 8.27%.

Revenue growth, annual

Embed this chart

Annual newest first

Period Revenue growth Change (points)
FY2025 44.7% 12.70
FY2024 32.0% 12.44
FY2023 19.6% 18.77
FY2022 0.79% (14.61)
FY2021 15.4% 5.45
FY2020 9.95% 6.11
FY2019 3.84% (3.77)
FY2018 7.61% 13.49
FY2017 −5.88% (12.21)
FY2016 6.33% 4.58

Quarterly newest first

Period Revenue growth Change (points)
Jun 2026 47.7% (7.87)
Mar 2026 55.5% 12.99
Dec 2025 42.6% (11.32)
Sep 2025 53.9% 16.22
42 more quarters

Against its own ten years

Low −5.88% High 44.7%
Ten-year median 7.61%
Current reading's percentile 100

Revenue growth against peers

Company Revenue growth
LLY Eli Lilly and Company 49.6%
ABBV AbbVie Inc. compare 10.4%
AMGN Amgen Inc. compare 9.10%
AZN AstraZeneca PLC compare 8.61%
JNJ Johnson & Johnson compare 7.80%
GILD Gilead Sciences, Inc. compare 5.52%
MRK Merck & Co., Inc. compare 4.64%
NVS Novartis AG compare 2.73%
PFE Pfizer Inc. compare −0.21%
Drug Manufacturers General industry median 6.66%
Healthcare sector median 8.27%
Market median 7.41%

What Revenue growth is

Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.

(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|

The full definition of Revenue growth →

More on LLY